Previous 10 | Next 10 |
Organicell Regenerative Medicine, Inc. (OTCMKTS:BPSR) (the “ Company ”), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies today announced that the Company and its therapeutic drug Zofin™ were recently featured in ...
Organicell Regenerative Medicine, Inc. (OTCBB: BPSR) (the “ Company ”), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it is now current in its SEC reporting requirements under the Securities Exchange A...
The Phase number of the clinical trial in the first paragraph, first sentence of release should read: Phase I/II (instead of Phase I/I). The updated release reads: ORGANICELL ANNOUNCES ADDITIONAL SITE FOR PHASE I/II CLINICAL TRIAL OF ZOFIN™ FOR TREATMENT OF COVID-19 ...
Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it is now enrolling patients at an additional site, Larkin Hospital North located in Hialeah, Florida for its Pha...
Organicell (BPSR) announces that several participants have been enrolled in its Phase 1/2 clinical trial evaluating Zofin in COVID-19 patients with moderate-to-severe acute respiratory distress syndrome. The subjects have been enrolled and treated at Larkin Hospital in Miami, FL.It expects to...
Anticipates Phase I/II trial completion by end of year Anticipates Phase IIb trial to begin in Q1 2021 Seeks to retain a global contract research organization (“CRO”) Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutic...
MIAMI, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it has recently entered into an agreement with Regenerative Care Network (“...
The FDA grants Zofin for the treatment of COVID-19 to Organicell Regenerative Medicine ([[BPSR]] -3.3%).Zofin is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any o...
Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted expanded access for an intermediate size population allowing its pr...
Organicell Commences Phase I/II Clinical Trial Enrollment Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted emerge...
News, Short Squeeze, Breakout and More Instantly...
Organicell Regenerative Medicine Inc Company Name:
BPSR Stock Symbol:
OTCMKTS Market:
Organicell Regenerative Medicine Inc Website:
Leading Therapeutics Research Company Begins New Era Common Stock to trade on OTCQB under the symbol "ZEOX" commencing March 5, 2024 FORT LAUDERDALE, FL / ACCESSWIRE / March 7, 2024 / ZEO ScientifiX, Inc . (OTCQB:ZEOX) (f/k/a Organicell Regenerative Medicine, Inc. - OTCQB:OCEL) today ...
Leading Therapeutics Research Company Begins New Era Common Stock to trade on OTCQB under the symbol "ZEOX" commencing March 5, 2024 FORT LAUDERDALE, FL / ACCESSWIRE / March 4, 2024 / ZEO ScientifiX, Inc . (OTCQB:ZEOX) (f/k/a Organicell Regenerative Medicine, Inc. - OTCQB: OCEL) today...
FORT LAUDERDALE, FL / ACCESSWIRE / November 27, 2023 / Organicell Regenerative Medicine Inc, (OTCQB:OCEL) ("Organicell" or the "Company"), today announced that it is implementing a 1-for-200 Reverse Split of the Company's common stock (the "Reverse Split") effective as of the close of business o...